This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
Lucy Chard
24 Jan 2024

5 big pharma companies agree to decarbonise operations in China

Following extensive talks, leading pharmaceutical companies sign an agreement to work with renewable energy companies to decarbonise their manufacturing supply chains in China and switch to renewables. 

Renewable energy in pharmaceuticals is considered one of the most important areas to tackle in terms of climate change, and an aspect that pharmaceutical companies have the means and room to improve. 

Making a statement move in this direction are five of the biggest global pharmaceutical and healthcare companies: AstraZeneca, Lonza, Novartis, Novo Nordisk, and Roche, who have all signed a renewable power agreement in China. The agreement is an industry first, with such big players setting the bar by agreeing to decarbonise their operations in China.

The companies, four of whom are already members of the Sustainable Markets Initiative Health Systems Task Force, announced their agreement, which is to last at least 3 years, at the World Economic Forum in Davos, Switzerland. The plan sets out to support China on its path to becoming carbon neutral, and aims to unlock 200 GWh of renewable electricity annually from 2024 across Jiangsu, Guangdong, Shanghai, and Beijing. The resulting reduction in emissions will amount to 120,000 tonnes of carbon dioxide equivalent (CO2e). 

The agreement comes after talks between the companies preceding COP28, where healthcare and pharma were broadly considered within sustainability initiatives and plans, more so than ever before. This latest agreement also lays the groundwork for other companies, with the option to join the initiative to work together to decarbonise their supply chains in China. Manufacturing supply chains are responsible for more than half of the emissions produced from the pharmaceutical sector, so changing to renewable energy will cut these considerably across the industry. 

To facilitate the switch to renewable energy Envision Energy, one of the biggest renewable energy firms in China, will be providing the electricity. The majority of the participating companies are involved in several other sustainability initiatives, and from this have developed further connections to a working group in China involving 16 Chinese companies spanning health, energy, and digital, to reduce the global impact China’s energy consumption has. 

The Sustainable Markets Initiative’s Health Systems Task Force continues to work with and encourage further partnerships to deliver more sustainable frameworks and tackle climate change throughout the sector. 

Lucy Chard
Digital Editor - Pharma

Related News

  • News How GLP-1 agonists are reshaping drug delivery innovations

    GLP-1 agonist drug products like Ozempic, Wegovy, and Mounjaro have taken the healthcare industry by storm in recent years. Originally conceived as treatment for Type 2 diabetes, the weight-loss effects of these products have taken on unprecedented int...
  • News NextPharma Achieves Carbon Neutrality for Scope 1 and 2 Emissions

    NextPharma has confirmed that it will achieve carbon neutrality for its Scope 1 and Scope 2 emissions starting January 1, 2025, marking a significant milestone in its sustainability journey.
  • News 2025 Pharma Trends Outlook: Collaborative Pharma – A New Era of Supply Chains

    A new year, a new Pharma Trends Outlook report! The 2025 Pharma Trends Outlook report examines key changes expected in the pharmaceutical industry for the coming year, particularly in regards to the supply chain.
  • News Closing 2024 with Editors' picks of top articles from the past year

    Coming to the end of 2024 and it’s certainly been a busy year, for CPHI and for the rest of the pharmaceutical and healthcare industry. Topics of conversation throughout the last 12 months have been varied, touching on the technical, to the polit...
  • News SCHOTT Pharma’s sustainable journey with CPHI

    Sustainability is of paramount importance in the pharmaceutical industry. See how a recent partnership between CPHI and SCHOTT Pharma has helped to highlight and accelerate their sustainability journey to reach global goals. 
  • News Day in the Life of a Green Chief Financial Officer

    Our latest look into the daily lives of the people behind the pharma community brings us to meet Juan Jose Piedra Galan, Global Financial Planning & Analysis Manager for Galderma, otherwise known as 'The Green CFO'.  
  • News CPHI Milan 2024 - From the Floor

    Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at...
  • News CPHI Podcast Series: analysing supplier audits with the PSCI

    This episode of the CPHI Podcast Series, hosted by Digital Editor Lucy Chard, goes through the results from the recent audits from the PSCI conducted on suppliers across the pharmaceutical industry, looking into ESG outcomes.